Biogen and Denali Halt Parkinson's Drug After Study Failure
Key Points
- BIIB122 failed to delay worsening of symptoms as measured by a combined score of movement and daily function, and also missed other key secondary measures
- The study enrolled 648 patients with early-stage Parkinson's disease, with the drug showing expected biological activity and acceptable safety but no clinical benefit
- Denali will continue testing the experimental drug in patients with a specific genetic mutation linked to Parkinson's disease
AI Summary
Summary
Key Development: Biogen and Denali Therapeutics announced Thursday they are discontinuing development of experimental Parkinson's disease drug BIIB122 following a mid-to-late stage clinical trial failure.
Trial Results: The drug failed to meet its primary endpoint in a study of 648 patients with early-stage Parkinson's disease. BIIB122 did not slow disease progression compared to placebo and failed to delay worsening of symptoms as measured by combined movement and daily function scores. The drug also showed no benefit on other key secondary measures.
Technical Performance: Despite demonstrating expected biological activity and an acceptable safety profile, BIIB122 did not translate these characteristics into clinical benefits for patients.
Companies Affected:
- Biogen (BIIB)
- Denali Therapeutics
Future Plans: While the broader development program is being halted, Denali Therapeutics will continue testing the experimental drug specifically in patients with a genetic mutation linked to Parkinson's disease.
Market Implications: This represents a significant setback for both companies' Parkinson's disease portfolios and the broader effort to develop disease-modifying treatments for this neurodegenerative condition. The failure highlights ongoing challenges in translating biological activity into meaningful clinical outcomes in Parkinson's research. The decision to continue testing in a genetically-defined patient subset suggests the companies believe there may still be potential in specific populations, though this represents a much narrower commercial opportunity than the original broad Parkinson's indication.
The discontinuation will likely impact both companies' pipeline valuations and future revenue projections in the neurology space.
Model Analysis Breakdown
| Model | Sentiment | Confidence |
|---|---|---|
| GPT-5-mini | Bearish | 80% |
| Claude 4.5 Haiku | Bearish | 80% |
| Gemini 2.5 Flash | Bearish | 90% |
| Consensus | Bearish | 83% |